Translocator Protein (TSPO) Expression in Platelets of Depressed Patients Decreases during Antidepressant Therapy

Abstract

Introduction: A promising candidate in the field of pharmacological treatment options regarding major depressive disorder (MDD) is the mitochondrial translocator protein (18 kDa) (TSPO). TSPO is crucial for neurosteroid synthesis, which is in turn important for the regulation of emotions. It has already been shown that TSPO expression in platelets of depressed patients is reduced compared to healthy subjects.

Methods: We measured TSPO levels in platelets of 37 depressed patients before and after 6 weeks of pharmacological treatment to test the hypotheses that i) such treatment would increase TSPO expression and ii) that this increase would be correlated with therapeutic response.

Results: Surprisingly, TSPO levels in platelets of all patients were significantly reduced after 6 weeks of treatment (p=0.044). Within the responder group, a non-significant trend towards greater TSPO level reduction could be observed.

Discussion: These results challenge our hypotheses that TSPO levels might increase during antidepressant therapy along with a decrease in depressive symptoms. Thus, we assume that TSPO expression in platelets is not a suitable state marker for MDD.

Key words

TSPO - platelets - depression - antidepressant - therapy response

• References

• 1 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006; 3: e442
• 2 Gadermann AM, Alonso J, Vilagut G et al. Comorbidity and disease burden in the National Comorbidity Survey Replication (NCS-R). Depress Anxiety 2012; 29: 797-806
• 3 Rupprecht R, Papadopoulos V, Rammes G et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010; 9: 971-988
• 4 Gut P, Zweckstetter M, Banati RB. Lost in translocation: the functions of the 18-kD translocator protein. Trends Endocrinol Metab 2015; 26: 349-356
• 5 Rone MB, Midzak AS, Issop L et al. Identification of a dynamic mitochondrial protein complex driving cholesterol import, trafficking, and metabolism to steroid hormones. Mol Endocrinol 2012; 26: 1868-1882
• 6 Nguyen N, Fakra E, Pradel V et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 2006; 21: 139-149
• 7 Schüle C, Nothdurfter C, Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog Neurobiol 2014; 113: 79-87
• 8 Papadopoulos V, Baraldi M, Guilarte TR et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-409
• 9 Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 2002; 40: 475-486
• 10 Maeda J, Higuchi M, Inaji M et al. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res 2007; 1157: 100-111
• 11 Chelli B, Pini S, Abelli M et al. Platelet 18 kDa translocator protein density is reduced in depressed patients with adult separation anxiety. Eur Neuropsychopharmacol 2008; 18: 249-254
• 12 Abelli M, Chelli B, Costa B et al. Reductions in platelet 18-kDa translocator protein density are associated with adult separation anxiety in patients with bipolar disorder. Neuropsychobiology 2010; 62: 98-103
• 13 Hamilton M. A rating scale for depression. Journal Neurol Neurosurg Psychiatry 1960; 23: 56-62
• 14 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994
• 15 Wittchen HU, Wunderlich U, Zaudig M et al. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. Göttingen: Hogrefe; 1997. Interviewheft
• 16 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 17 Gilmer 1 WS, Gollan JK, Wisniewski SR et al. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. J Clin Psychiatry 2008; 69: 1246-1256
• 18 Nussbaumer B, Morgan LC, Reichenpfader U et al. Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis. CNS Drugs 2014; 28: 699-712
• 19 Sarubin N, Nothdurfter C, Schmotz C et al. Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression. Psychoneuroendocrinology 2014; 39: 141-151
• 20 Riedel 1 M, Möller HJ, Obermeier M et al. Response and remission criteria in major depression – a validation of current practice. J Psychiatr Res 2010; 44: 1063-1068
• 21 Weizman A, Burgin R, Harel Y et al. Platelet peripheral-type benzodiazepine receptor in major depression. J Affect Disord 1995; 33: 257-261
• 22 Setiawan E, Wilson AA, Mizrahi R et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015; 72: 268-275
• 23 Hannestad J, DellaGioia N, Gallezot JD et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [¹¹C]PBR28 PET study. Brain Behav Immun 201 33: 131-138
• 24 Danovich L, Veenman L, Leschiner S et al. The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. Eur Neuropsychopharmacol 2008; 18: 24-33
• 25 Dennis T, Beauchemin V, Lavoie N. Antidepressants reverse the olfactory bulbectomy-induced decreases in splenic peripheral-type benzodiazepine receptors in rats. Eur J Pharmacol 1995; 272: 279-288
• 26 Leschiner S, Weizman R, Shoukrun R et al. Tissue-specific regulation of the peripheral benzodiazepine receptor by antidepressants and lithium. Neuropsychobiology 2000; 42: 127-134
• 27 Bae KR, Shim HJ, Balu D et al. Translocator protein 18 kDa negatively regulates inflammation in microglia. J Neuroimmune Pharmacol 2014; 9: 424-437
• 28 Uzunova V, Sheline Y, Davis JM et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998; 95: 3239-3244
• 29 Costa B, Pini S, Abelli M et al. Role of translocator protein (18 kDa) in adult separation anxiety and attachment style in patients with depression. Curr Mol Med 2012; 12: 483-487
• 30 Wolf L, Bauer A, Melchner D et al. Enhancing neurosteroid synthesis – relationship to the pharmacology of translocator protein (18 kDa) (TSPO) ligands and benzodiazepines. Pharmacopsychiatry 2015; 48: 72-77